Iradimed (IRMD) CEO sells 5,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Roger E. Susi, who serves as CEO, President, Chairman and is reported as a 10% owner of Iradimed Corp (IRMD), reported sales of company common stock on 10/06/2025 under a Rule 10b5-1 trading plan adopted 6/16/2025. The Form 4 shows a sale of 4,800 shares at a weighted average price of $71.70 and a separate sale of 200 shares at $72.27, for a total of 5,000 shares disposed. The filing also discloses substantial indirect holdings: 2,342,700 shares indirectly held via a trust and other related trusts holding large positions. The reporting person disclaims beneficial ownership of certain shares except for pecuniary interest.

Insights

Corporate Governance Analyst

Insider sales under a 10b5-1 plan show routine liquidity while major indirect holdings remain large.

The sales were executed under a documented Rule 10b5-1 plan adopted on 6/16/2025, which provides an affirmative defense for planned trades when properly implemented. The filing reports a weighted average sale price of $71.70 for the larger block and $72.27 for the smaller block on 10/06/2025.

Because the reporting person retains substantial indirect positions (for example 2,342,700 shares by a trust), these disposals appear limited relative to overall family holdings; monitor future Form 4 filings and any amendments for changes in trading pace or plan termination within a near-term horizon of Q4 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		S(1)		4,800	D	$71.7(2)	2,342,700	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	10/06/2025		S(1)		200	D	$72.27	2,342,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(3)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $71.25 to $72.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Roger E. Susi report on Form 4 for IRMD?

The filing reports sales of 4,800 shares at a weighted average price of $71.70 and 200 shares at $72.27 on 10/06/2025.

Were the transactions made under a 10b5-1 plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 6/16/2025.

How much IRMD stock does the filing show indirectly owned by related trusts?

The Form 4 discloses 2,342,700 shares indirectly held by a trust (and other trust holdings listed such as 2,342,500 and 2,062,500 in related entries).

What is the reporting person’s relationship to Iradimed?

The reporting person, Roger E. Susi, is listed as CEO, President, Chairman and a 10% owner.

Does the filer claim full beneficial ownership of the shares reported?

The filer disclaims beneficial ownership of certain securities except to the extent of pecuniary interest, per the filing's explanatory note.